Poolbeg Pharma received initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza.
Key highlights from the study:
- No further clinical activity is required to complete the objectives of the trial, bringing the recruitment and clinical phase to a close on schedule
- No serious adverse events reported. POLB 001 was found to be safe and well tolerated
- Data analysis has commenced and full data read-out is expected in Q2 2023
- The comprehensive dataset is expected to facilitate progression of the product to the next clinical phase for potential partners
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.